In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 64 for your search:
Cancer Type/Condition:  Islet cell tumor
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181202, NCT01525550

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793

3.

Phase: Phase IV
Type: Natural history/Epidemiology
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A-97-52030-270, NCT02075606

4.

Phase: Phase III
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MKT-2012-nCLE-02, NCT01563133

5.

Phase: Phase II, Phase I
Type: Tissue collection/Repository
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 93-102, NCT00579163

6.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 11I03, NCI-2011-02939, STU00053541, NCT01465659

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 andover
Sponsor: Other
Protocol IDs: 201303150, NCT01784861

8.

Phase: Phase II, Phase I
Type: Diagnostic
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 68Ga-DOTATATE, NCT02038738

9.

Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 092/11, NCT02078843

10.

Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02086, CDR0000653790, MC0845, 8233, N01CM00100, N01CM00038, P30CA015083, N01CM00099, N01CM00071, N01CM00070, N01CM00032, MAYO-MC0845, NCT01010126

11.

Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MAW002, NCT00978211

12.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: EudraCT 2006-004748-22, NCT01203306

13.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 78,256, NCT01237457

14.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-274, NCT01466036

15.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NET0012, NCI-2011-03497, SU-10282011-8571, END0012, NCT01525082

16.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBEZ235Z2401, 2012-000769-19, NCT01628913

17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HE 67/12, 2011-006160-48, NCT01648465

18.

Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 2012-000994-22, NCT01673906

19.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: E2211, NCI-2012-02007, U10CA021115, NCT01824875

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IJBMNLUMEN, 2012-003666-41, NCT01842165

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TEPNET, NCT01845675

22.

Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-17410, CSMS995AUS64T, NCT01886287

23.

Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130193, 13-C-0193, NCT01967537

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: FMTN- ?- GEPNET, NCT01994213

25.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: E2212, NCI-2013-02484, ECOG-E2212, U10CA021115, NCT02031536
1    
New Search